HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dyck, P. J. Articles by Dyck, P. J. B. Search for Related Content PubMed PubMed Citation Articles by Dyck, P. J. Articles by Dyck, P. J. B. Social Bookmarking                What's this?

Monotonicity of Nerve Tests in Diabetes

Subclinical nerve dysfunction precedes diagnosis of polyneuropathy

¹ Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota
² Division of Biostatistics, Mayo Clinic College of Medicine, Rochester, Minnesota

Address correspondence and reprint requests to Peter J. Dyck, MD, Mayo Clinic College of Medicine, Department of Neurology, 200 First St. SW, Rochester, MN 55905. E-mail: dyck.peter{at}mayo.edu

OBJECTIVE—The objective of this study was to test whether monotone worsening of nerve function, attributable to diabetes, can be demonstrated before criteria for diabetic sensorimotor polyneuropathy (DSPN) have been met. Which nerve tests are best?

RESEARCH DESIGN AND METHODS—From a prevalence cohort of 504 individuals in the Rochester Diabetic Neuropathy study (RDNS), we identified 238 individuals (group 1) who at first examination were without polyneuropathy (DSPN) by a sum score of the normal deviates (from percentiles) of five attributes of nerve conduction of the legs (i.e., their five nerve conduction normal deviate values were <97.5th percentile) and were followed longitudinally two or more times. Of these 238, 90 (group 2) were followed six or more times at yearly or biyearly intervals. We compared different nerve tests for the ones most sensitive and reliable in showing latent nerve dysfunction and monotone (the extent to which a variable measured repeatedly over time reveals a significant trend of worsening or improvement).

RESULTS—In group 1 patients, the mean sum score of five attributes of nerve conduction ( 5 NC nds) at baseline was 1.08 and at the last examination (only patients with 5 NC nds <97.5th percentile) was 3.63, markedly higher than that in healthy subjects (only of individuals with 5 NC nds <97.5th percentile) (–0.12), indicating a subtle latent shift of nerve conduction tests toward abnormality. Serial evaluations of many individual and especially sum scores of nerve conduction tests in group 2 patients showed statistically significant worsening with time, even when nerve conduction tests were still well within normal limits. Neurologic signs also worsened but barely to significant levels; however, symptoms and quantitative sensation tests did not. Considering the composite score 5 NC nds, 42 (of 90 group 2 patients) showed significant worsening, 22 were still without DSPN by nerve conduction test criteria, and some were even below the 50th percentile at the last evaluation.

CONCLUSIONS—Subtle and latent functional worsening of nerve conduction can be demonstrated even before nerve conduction test criteria for DSPN have been met. For demonstrating monotone worsening, the order (from best to worst) of tests was: some composite scores of nerve conduction and individual attributes of nerve conduction. We did not show monotone worsening of symptoms or of quantitative sensation test results. In multivariate analysis of risk factors and their association with worsening 5 NC nds, 24-h microalbuminuria (a marker of microvessel disease) was found to be a significant covariate, an indication that the asymptomatic alterations of nerve conduction are meaningful.

Abbreviations: CNA, Clinical Neuropathy Assessment • DSPN, diabetic sensorimotor polyneuropathy • NSC, Neuropathy Symptoms and Change • NIS, Neuropathy Impairment Score • QST, quantitative sensation test • RDNS, Rochester Diabetic Neuropathy Study • RDNS-HS, RDNS of healthy subjects

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				P. J. Dyck, J. E. Norell, H. Tritschler, K. Schuette, R. Samigullin, D. Ziegler, E. J. Bastyr III, W. J. Litchy, and P. C. O'Brien Challenges in Design of Multicenter Trials: End points assessed longitudinally for change and monotonicity Diabetes Care, October 1, 2007; 30(10): 2619 - 2625. [Abstract] [Full Text] [PDF]

				S. Tesfaye, R. Tandan, E. J. Bastyr III, K. A. Kles, V. Skljarevski, K. L. Price, and for the Ruboxistaurin Study Group Factors That Impact Symptomatic Diabetic Peripheral Neuropathy in Placebo-Administered Patients From Two 1-Year Clinical Trials Diabetes Care, October 1, 2007; 30(10): 2626 - 2632. [Abstract] [Full Text] [PDF]

				D. Selvarajah, I. D. Wilkinson, C. J. Emery, N. D. Harris, P. J. Shaw, D. R. Witte, P. D. Griffiths, and S. Tesfaye Early Involvement of the Spinal Cord in Diabetic Peripheral Neuropathy Diabetes Care, December 1, 2006; 29(12): 2664 - 2669. [Abstract] [Full Text] [PDF]

				P. J. Dyck, J. L. Davies, V. M. Clark, W. J. Litchy, P. J. B. Dyck, C. J. Klein, R. A. Rizza, J. M. Pach, R. Klein, T. S. Larson, et al. Modeling Chronic Glycemic Exposure Variables as Correlates and Predictors of Microvascular Complications of Diabetes Diabetes Care, October 1, 2006; 29(10): 2282 - 2288. [Abstract] [Full Text] [PDF]

				P J Dyck and P C O'Brien Polyneuropathy dysfunction scores J. Neurol. Neurosurg. Psychiatry, August 1, 2006; 77(8): 899 - 900. [Full Text] [PDF]